NEW YORK, Nov 28- Anika Therapeutics Inc. said on Tuesday it received conditional approval from U.S. health regulators for its injectable filler for facial wrinkles.
The company said it expects final approval from the Food and Drug Administration by the end of this year, sending Anika shares more than 21 percent higher.
Anika did not specify what conditions the FDA had set before the agency will give its outright approval for the sale of the cosmetic tissue augmentation treatment.
ANIK is trading substantially up today at $14.81; that's up 3.25 or 29%.
Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products for tissue protection and healing. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA is one of them simplest of the glycosaminoglycans which is a repeating sugar molecules up to 25,000 units. It is thought to play a role in resisting compressive forces in tissues and joints.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment